Considering that patients trialed on NIPPV prior to IMV were associated with no mortality disadvantage to patients treated with only IMV, trialing patients on NIPPV may identify responders and avoid complications associated with IMV. Increased ventilator support, need of vasopressors, SVTs, and high dose steroids reflect higher mortality and palliative care involvement should be considered as early as possible if a lung transplant is not an option.
Keyphrases
- mechanical ventilation
- respiratory failure
- end stage renal disease
- palliative care
- interstitial lung disease
- high dose
- newly diagnosed
- ejection fraction
- acute respiratory distress syndrome
- chronic kidney disease
- intensive care unit
- peritoneal dialysis
- rheumatoid arthritis
- prognostic factors
- cardiovascular disease
- type diabetes
- low dose
- cardiovascular events
- idiopathic pulmonary fibrosis
- patient reported outcomes
- coronary artery disease
- liver failure
- patient reported